Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenjiang Zhao

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Bioorganic Chemistry|December 15, 2021
Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitorsDou Dou, Wenjie Sha, Yanyan Diao, et al.
Bioorganic Chemistry|June 6, 2022
Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitorsRongrong Su, Yanyan Diao, Wenjie Sha, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2025
Structure-based design of novel pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as potent noncovalent Bruton's tyrosine kinase (BTK) inhibitorsChaoquan Tian, Wenjie Liao, Zhixiao Yu, et al.
Oncotarget|August 18, 2016
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptorQiao Li, Lina Quan, Jiankun Lyu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 28, 2022
Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasmsHuan Ge, Caolin Wang, Chaoquan Tian, et al.
Journal of Medicinal Chemistry|June 29, 2024
Development of Degraders of Cyclin-Dependent Kinases <b>4</b> and <b>6</b> Based on Rational Drug DesignHuan He, Xingsen Zhang, Jie Wang, et al.
Journal of Medicinal Chemistry|June 26, 2025
Design, Synthesis, and Biological Evaluation of Macrocyclic 2-Amino-4-phenylaminopyrimidine Derivatives as Potent JAK2 InhibitorsWenyi Mei, Xiaotong Jia, Feng Hu, et al.
Journal of Medicinal Chemistry|June 3, 2025
Discovery of a Proteolysis-Targeting Chimera Degrader of JAK2 as a Potential Therapeutic Agent for JAK2-Mediated Myeloproliferative NeoplasmsCaolin Wang, Ziqi Chen, Siyu Wang, et al.
Bioorganic & Medicinal Chemistry Letters|January 10, 2012
Discovery of novel selective inhibitors for EGFR-T790M/L858RFang Bai, Hongyan Liu, Linjiang Tong, et al.
Journal of Chemical Information and Modeling|October 15, 2011
Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology modelShiliang Li, Yi Zhou, Weiqiang Lu, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Bioorganic Chemistry|December 15, 2021
Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitorsDou Dou, Wenjie Sha, Yanyan Diao, et al.
Bioorganic Chemistry|June 6, 2022
Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitorsRongrong Su, Yanyan Diao, Wenjie Sha, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2025
Structure-based design of novel pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as potent noncovalent Bruton's tyrosine kinase (BTK) inhibitorsChaoquan Tian, Wenjie Liao, Zhixiao Yu, et al.
Oncotarget|August 18, 2016
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptorQiao Li, Lina Quan, Jiankun Lyu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 28, 2022
Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasmsHuan Ge, Caolin Wang, Chaoquan Tian, et al.
Journal of Medicinal Chemistry|June 29, 2024
Development of Degraders of Cyclin-Dependent Kinases <b>4</b> and <b>6</b> Based on Rational Drug DesignHuan He, Xingsen Zhang, Jie Wang, et al.
Journal of Medicinal Chemistry|June 26, 2025
Design, Synthesis, and Biological Evaluation of Macrocyclic 2-Amino-4-phenylaminopyrimidine Derivatives as Potent JAK2 InhibitorsWenyi Mei, Xiaotong Jia, Feng Hu, et al.
Journal of Medicinal Chemistry|June 3, 2025
Discovery of a Proteolysis-Targeting Chimera Degrader of JAK2 as a Potential Therapeutic Agent for JAK2-Mediated Myeloproliferative NeoplasmsCaolin Wang, Ziqi Chen, Siyu Wang, et al.
Bioorganic & Medicinal Chemistry Letters|January 10, 2012
Discovery of novel selective inhibitors for EGFR-T790M/L858RFang Bai, Hongyan Liu, Linjiang Tong, et al.
Journal of Chemical Information and Modeling|October 15, 2011
Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology modelShiliang Li, Yi Zhou, Weiqiang Lu, et al.
Pageof 10